indication
as of 2026-07-01Autistic Disorder
Competitive landscape projected to Patient group/Passvers’s launch window
Competitive set
2
2 approved · 0 pipeline
Projection timeline
actual past → guided future · protection walls overlaid
21 events
2020
2024
2028
2032
2036
2040
today
Patient group/Passvers launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff
Competitive set
resolved drugs with trials in this indicationdrugCompleted
US-approved 2010 · Latuda
Phase 33 trials
Protection2031
drugCompleted
US-approved 1993 · RISPERDAL
Phase 41 trial
Protection2042
Market size
prevalence as a range, not a number